Device Therapy in Refractory Heart Failure
Keywords:
heart failure, left ventricular assist device, heart transplantation, cardiac resynchronization therapy, implantable cardioverter defibrillatorAbstract
Advanced heart failure (HF) has been defined as persistent symptoms that limit daily life despite optical medical therapy, corresponding to New York Heart Association (NYHA) class III/IV symptoms or to the newer classification of stage D HF (ACC/AHA staging classification). It affects 10% of the HF population and is associated with a poor quality of life, recurrent hospitalizations and a mortality approaching 50% at 1 year and 80% at 5 years. Despite the widespread use of angiotensin converting enzyme (ACE) inhibitors, beta adrenergic blocking agents and spironolactone which improve the prognosis in mild to moderate stages, HF remains a progressive disease leading to decompensation and demand of both inotropic agents (class III recommendation according to ACC/AHA guidelines, considered solely for palliation in patients with end-stage disease) and diuretics to treat hypotension, impaired renal function and pulmonary congestion.
Heart transplantation (HT) is associated with nearly 90% 1-year survival, 60% 10-year survival and 95% freedom from symptoms and activity limitations in survivors throughout the follow-up period. Nevertheless, the lack of available donors and the large number of patients, who do not meet the criteria for transplantation, have spurred interest in cardiac resynchronization therapy (CRT) and mechanical circulatory support (MCS), providing alternatives for patients waiting for HT (bridge to transplantation, BTT), patients who are ineligible for HT (destination therapy, DT) or patients who are anticipated to recover after left ventricular unloading (bridge to recovery, BTR)... (excerpt)Downloads
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).